For example, A1CF promotes NASH and HCC64, ESRP2 loss promotes HCC and lower expression predicts worse survival32, HNRNPAB induces EMT and promotes HCC metastasis65, the poly(C)-binding protein PCBP2 is upregulated in HCC and promotes proliferation66, SFPQ and RBM8A mediate resistance to platinum drugs in HCC67,68, RBMS1 blocks ferroptosis in HCC69, MATR3 promotes HCC progression70, SART3 is an immunotherapy target in HCC71, ZCRB1 is a signature gene for HCC72, and down regulation of CELF2 or CPEB3 promotes HCC73, but the targets for many of these splicing factors remain to be determined. This evidence concerns the gene CELF2 and metabolic dysfunction-associated steatohepatitis.